Overproduction of aldosterone represents a major medical challenge, leading to complications such as hypertension. In this context, the use of 61Cobalt-labeled eplerenone, combined with targeted X-rays, is emerging as a novel approach. This promising method aims to selectively target affected adrenal tissue while minimizing damage to surrounding tissue. Preclinical studies have shown potential efficacy in animal models, with encouraging safety results. However, clinical trials are needed to validate this method in human patients. This approach opens the way to personalized and effective treatment options for patients suffering from aldosterone overproduction, representing a significant advance in the field of hypertension management.